BETA
Single-use surgical visualization systems combining Summit arthroscopes with cloud-connected workflow software.
Pristine Surgical develops single-use endoscopic visualization technology. Its commercial Summit arthroscope provides 4K imaging and connects with Pristine Connect software for image/video handling and inventory workflows. The company announced U.S.-wide availability in November 2023.
The commercial model centers on scopes by subscription and distribution through selected partners. The company positions this against the maintenance, reprocessing and capital requirements of reusable systems. Those economic and sustainability claims depend on facility usage, pricing and local processes.
The current leadership page identifies Rich McKillop as CEO and Chief Revenue Officer, while earlier launch announcements name previous leaders. Laparoscopy and flexible endoscopy are described as pipeline areas; their inclusion on a development roadmap does not establish commercial availability or clearance of every planned device.
Summit/Pristine Arthroscopic Visualization System has clearance K223244 and documented commercial release. Two earlier Pristine Scope decisions are retained as history rather than assumed to cover every current Summit configuration. Laparoscopy and flexible endoscopy remain separate development areas. [10][14][4][13][12][1]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [8][6]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
4K single-use arthroscope and connected workflow software; commercial system separated from future flexible/laparoscopic products. [10][14]
FDA-clearedCommercially offered; exact model and country availability should be confirmed with the manufacturer.
Summit arthroscopy is commercial. Laparoscopy and flexible endoscopy remain pipeline areas in the reviewed company materials. [10][13]
Company announced broad U.S. availability after a limited rollout, including distribution through selected partners. [13]
FDA decision predates the January 2023 public clearance announcement. [14]
Accessed 10/29/2026